Cardiff Oncology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report covers the Annual Meeting of Stockholders held by Cardiff Oncology, Inc. on June 9, 2022. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol CRDF.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
A total of 29,365,861 shares were represented at the meeting, constituting a quorum. The following matters were submitted to a vote:
- Proposal 1 (Election of Directors): All seven nominees were elected. Renee P. Tannenbaum, Pharm.D., received the highest number of "Withhold" votes (3,059,013) compared to other directors, though she was still elected.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2022.
- Proposal 3 (Equity Incentive Plan): Stockholders approved the amendment to the Company's 2021 Omnibus Equity Incentive Plan.
- Proposal 4 (Say-on-Pay): The advisory vote on executive compensation was approved, though it was a close vote with 7,931,026 "For" votes versus 7,356,186 "Against" votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the amendment to the 2021 Omnibus Equity Incentive Plan approved in Proposal 3.
- Review the "Say-on-Pay" vote results, noting the significant number of "Against" votes (approximately 48% of the votes cast excluding broker non-votes).
- Confirm the tenure and background of the newly elected directors, particularly Renee P. Tannenbaum, who received the most dissenting votes.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.